Novel water-soluble substituted pyrrolo[3,2-d]pyrimidines: Design, synthesis, and biological evaluation as antitubulin antitumor agents

Pharmaceutical Research

Volumn 29, Issue 11, 2012, Pages 3033-3039

  Gangjee, Aleem ^a   Pavana, Roheeth K ^a   Li, Wei ^a   Hamel, Ernest ^b   Westbrook, Cara ^c   Mooberry, Susan L ^c,d  

^a DUQUESNE UNIVERSITY   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c Mays Cancer Center at UT Health San Antonio   (United States)

^d UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

antitubulin; colchicine site binders; drug design; microtubule depolymerizer; pyrrolo 3,2 d pyrimidines

Indexed keywords

6 METHOXY 1 (2 METHYL 5H PYRROLO[3,2 D]PYRIMIDIN 4 YL) 1,2,3,4 TETRAHYDROQUINOLINE; ANTINEOPLASTIC AGENT; COLCHICINE; COMBRETASTATIN A4; N (2,4 DIMETHOXYPHENYL) 2 METHYL 5H PYRROLO[3,2 D]PYRIMIDIN 4 AMINE; N (4 METHOXYPHENYL) 2 METHYL 5H PYRROLO[3,2 D]PYRIMIDIN 4 AMINE; N (4 METHOXYPHENYL) N METHYL 5H PYRROLO[3,2 D]PYRIMIDIN 4 AMINE; N (4 METHOXYPHENYL) N,2 DIMETHYL 5H PYRROLO[3,2 D]PYRIMIDIN 4 AMINE; N (4 METHOXYPHENYL) N,2 DIMETHYL 7H PYRROLO[2,3 D]PYRIMIDIN 4 AMINE; N (4 METHOXYPHENYL) N,2,6 TRIMETHYL 5H PYRROLO[3,2 D]PYRIMIDIN 4 AMINE; N (4 METHOXYPHENYL) N,2,6 TRIMETHYL 6,7 DIHYDRO 5H CYCLOPENTA[D]PYRIMIDIN 4 AMINE; N,2 DIMETHYL N PHENYL 5H PYRROLO[3,2 D]PYRIMIDIN 4 AMINE; N4 (4 METHOXYPHENYL) 6 METHYL 5H PYRROLO[3,2 D]PYRIMIDINE 2,4 DIAMINE; N4 (4 METHOXYPHENYL) N4,6 DIMETHYL 5H PYRROLO[3,2 D]PYRIMIDINE 2,4 DIAMINE; PYRIMIDINE DERIVATIVE; PYRROLO[3,2 D]PYRIMIDINE DERIVATIVE; TUBULIN; UNCLASSIFIED DRUG; WATER;

ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CENTRAL NERVOUS SYSTEM TUMOR; CHEMICAL MODIFICATION; COLON CANCER; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG BINDING; DRUG CYTOTOXICITY; DRUG DESIGN; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG SOLUBILITY; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN; HUMAN CELL; IC 50; INHIBITION KINETICS; KIDNEY CANCER; LEUKEMIA CELL LINE; LUNG NON SMALL CELL CANCER; MELANOMA; MICROTUBULE ASSEMBLY; PRIORITY JOURNAL; PROSTATE CANCER; STRUCTURE ACTIVITY RELATION;

ANTINEOPLASTIC AGENTS; BINDING SITES; CELL LINE, TUMOR; CELL PROLIFERATION; COLCHICINE; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; PYRIMIDINES; PYRROLES; STRUCTURE-ACTIVITY RELATIONSHIP; TUBULIN; TUBULIN MODULATORS; WATER;

EID: 84867855771     PISSN: 07248741     EISSN: 1573904X     Source Type: Journal    
DOI: 10.1007/s11095-012-0816-3     Document Type: Article

References (24)

1. Gangjee A, Zhao Y, Lin L, Raghavan S, Roberts EG, Risinger AL, et al. Synthesis and discovery of water-soluble microtubule targeting agents that bind to the colchicine site on tubulin and circumvent Pgp mediated resistance. J Med Chem. 2010;53(22):8116-28.
2. Gangjee A, Zhao Y, Lin L, Raghavan S, Roberts EG, Risinger AL, et al. Corrections to synthesis and discovery of water-soluble microtubule targeting agents that bind to the colchicine site on tubulin and circumvent Pgp mediated resistance. J Med Chem 2011;54(3):913.
3. Leonard GD, Fojo T, Bates SE. The role of ABC transporters in clinical practice. Oncologist. 2003;8:411-24.
4. Ling V. Multidrug resistance: molecular mechanisms and clinical relevance. Cancer Chemother Pharmacol. 1997;40:S3-8.
5. Ferrandina G, Zannoni GF, Martinelli E, Paglia A, Gallotta V, Mozzetti S, et al. Class III β-tubulin overexpression is a marker of poor clinical outcome in advanced ovarian cancer patients. Clin Cancer Res. 2006;12:2774-9.
6. Mozzetti S, Ferlini C, Concolino P, Filippetti F, Raspaglio G, Prislei S, et al. Class III β-tubulin overexpression is a prominent mechanism of paclitaxel resistance in ovarian cancer patients. Clin Cancer Res. 2005;11:298-305.
7. Rosell R, Scagliotti G, Danenberg KD, Lord RVN, Bepler G, Novello S, et al. Transcripts in pretreatment biopsies from a three-arm randomized trial in metastatic non-small-cell lung cancer. Oncogene. 2003;22:3548-53.
8. Seve P, Isaac S, Tredan O, Souquet P-J, Pacheco Y, Perol M, et al. Expression of class III β-tubulin is predictive of patient outcome in patients with non-small cell lung cancer receiving vinorelbine-based chemotherapy. Clin Cancer Res. 2005;11:5481-6.
9. Tommasi S, Mangia A, Lacalamita R, Bellizzi A, Fedele V, Chiriatti A, et al. Cytoskeleton and paclitaxel sensitivity in breast cancer: the role of β-tubulins. Int J Cancer. 2007;120:2078-85.
10. Sizova OS, Modnikova GA, Glushkov RG, Solov'eva NP, Ryabokon NA, Chernov VA, et al. Synthesis and biological activity of 4,7-substituted pyrrolo[3,2-d]pyrimidines. Khim-Farm Zh. 1984;18:958-62.
11. Gangjee A, Li W, Yang J, Kisliuk RL. Design, synthesis, and biological evaluation of classical and nonclassical 2-amino-4-oxo-5-substituted-6- methylpyrrolo[3,2-d]pyrimidines as dual thymidylate synthase and dihydrofolate reductase inhibitors. J Med Chem. 2008;51(1):68-76.
12. Haraguchi K, Horii C, Yoshimura Y, Ariga F, Tadokoro A, Tanaka H. An access to the β-anomer of 4'-thio-c-ribonucleosides: Hydroboration of 1-C-aryl- or 1-C-heteroaryl-4-thiofuranoid glycals and its regiochemical outcome. J Org Chem. 2011;76:8658-69.
13. Stadlwieser J, Schmidt B, Bernsmann H, Dunkern T, Benediktus E, Pahl A, et al. inventors; Nycomed GmbH, Germany. assignee. Methylpyrrolopyrimidinecarboxamides as phosphodiesterase type 5 inhibitors and their preparation and use in the treatment of diseases. Patent WO2011023693A1. 2011.
14. Lee L, Robb LM, Lee M, Davis R, Mackay H, Chavda S, et al. Design, synthesis, and biological evaluations of 2,5-diaryl-2,3-dihydro-1,3,4- oxadiazoline analogs of combretastatin-A4. J Med Chem. 2010;53(1):325-34.
15. Skehan P, Storeng R, Scudiero D, Monks A, McMahon J, Vistica D, et al. New colorimetric cytotoxicity assay for anticancer-drug screening. J Natl Cancer Inst. 1990;82(13):1107-12.
16. Boyd MR, Paull KD. Some practical considerations and applications of the national cancer institute in vitro anticancer drug discovery screen. Drug Develop Res. 1995;34(2):91-109.
17. Risinger AL, Jackson EM, Polin LA, Helms GL, LeBoeuf DA, Joe PA, et al. The taccalonolides: microtubule stabilizers that circumvent clinically relevant taxane resistance mechanisms. Cancer Res. 2008;68(21):8881-8.
18. Hamel E. Evaluation of antimitotic agents by quantitative comparisons of their effects on the polymerization of purified tubulin. Cell Biochem Biophys. 2003;38(1):1-21.
19. Hamel E, Lin CM. Separation of active tubulin and microtubule-associated proteins by ultracentrifugation and isolation of a component causing the formation of microtubule bundles. Biochemistry. 1984;23(18):4173-84.
20. Lin CM, Ho HH, Pettit GR, Hamel E. Antimitotic natural products combretastatin A-4 and combretastatin A-2: Studies on the mechanism of their inhibition of the binding of colchicine to tubulin. Biochemistry. 1989;28(17):6984-91.
21. Borisy GG. A rapid method for quantitative determination of microtubule protein using deae-cellulose filters. Anal Biochem. 1972;50(2):373-85.
22. Verdier-Pinard P, Lai J-Y, Yoo H-D, Yu J, Marquez B, Nagle DG, et al. Structure-activity analysis of the interaction of curacin A, the potent colchicine site antimitotic agent, with tubulin and effects of analogs on the growth of MCF-7 breast cancer cells. Mol Pharmacol. 1998;53(1):62-76.
23. Hamel E, Lin CM. Stabilization of the colchicine-binding activity of tubulin by organic acids. Biochim Biophys Acta. 1981;675(2):226-31.
24. Shoemaker RH. The NCI60 human tumour cell line anticancer drug screen. Nat Rev Cancer. 2006;6(10):813-23.